CLL

Relapsed or Refactory

Criteria to qualify for study: Drug used in study:
  • CD20 positive
  • Must have at least on bi-dimensionally measurable lesion ≥ 1.5 cm.
  • Must have had at least one prior anti­cancer treatment.

SCRI  HEMREF-34

An Open-Label, Phase lb Study of IPI-145 in combination with Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects with
Lymphoma or Chronic Lymphocytic Leukemia

 

 

 

 

 


Relapsed, Refactory or Untreated